News
Media
Conferences
Events
Publication
CME/CE
Resources
Editorial Advisory Board
Partners
Subscribe

Opinion|Videos|December 10, 2024

Significant Barriers and Unmet Needs for Patients With Atopic Dermatitis

Author(s)Robert J. Casquejo, PA-C

Key Takeaways

Panelists discuss how patients with atopic dermatitis face numerous obstacles to optimal care, including limited access to specialists, high treatment costs, inadequate insurance coverage, and the need for more effective long-term management options.

Episodes in this series

1 KOL is featured in this series.

EP. 1 The Effect of Atopic Dermatitis Across Patient Populations

1 KOL is featured in this series.

EP. 2 Psychosocial Burden and Quality of Life of Patients with Atopic Dermatitis

1 KOL is featured in this series.

EP. 3 Balancing Patient Needs and Telemedicine Considerations

1 KOL is featured in this series.

EP. 4 Variation of Atopic Dermatitis Challenges in Children and Adults

1 KOL is featured in this series.

EP. 5 Significant Barriers and Unmet Needs for Patients With Atopic Dermatitis

1 KOL is featured in this series.

EP. 6 Clinical Challenges in Treating Atopic Dermatitis

1 KOL is featured in this series.

EP. 7 Differentiating Pediatric Atopic Dermatitis from Other Skin Conditions

1 KOL is featured in this series.

EP. 8 Unique Challenges and Considerations for Treating Pediatric Atopic Dermatitis

1 KOL is featured in this series.

EP. 9 Engaging Parents, Caregivers, and Schools in the Management of Pediatric Atopic Dermatitis

1 KOL is featured in this series.

EP. 10 New and Upcoming Therapies in Atopic Dermatitis

1 KOL is featured in this series.

EP. 11 Comparing and Contrasting the Current Armamentarium for Treating Atopic Dermatitis

1 KOL is featured in this series.

EP. 12 Patient Adherence and the Future of Atopic Dermatitis Treatment

1 KOL is featured in this series.

EP. 13 Providing Support for Comorbidities and Psychological Health in Patients with Atopic Dermatitis

1 KOL is featured in this series.

EP. 14 Patient Education and Key Considerations for Initiating Topical JAK Inhibitors

1 KOL is featured in this series.

EP. 15 Precision Medicine’s Effect on Atopic Dermatitis Treatment

EP. 16 Unveiling the Complexities of Atopic Dermatitis Care

EP. 16 Unveiling the Complexities of Atopic Dermatitis Care

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Latest CME

Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis

Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis

Joseph Gorelick, MSN, FNP-C

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Brad P. Glick, DO, MPH, FAAD

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Hilary Baldwin; Neal Bhatia, MD

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

In-Person Event

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

June 17-19, 2026

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Trending on Dermatology Times

Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results

Reviewing Type 2 Inflammation Through a Different Lens

Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott

Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic

Dermatology Conferences and Meetings Calendar: December 2025

© 2025 MJH Life Sciences^®

All rights reserved.